PriceTargets.com logo

Item 9 Labs - INLB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 11/20/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for INLB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Item 9 Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INLB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INLB

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Item 9 Labs in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for INLB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Item 9 Labs. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/23/2021Noble FinancialReiterated RatingBuy$4.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Item 9 Labs logo
Item 9 Labs Corp. operates as a vertically integrated cannabis operator and dispensary franchisor in the United States. The company produces cannabis and cannabis-related products in various categories, such as flower; concentrates; distillates; and hardware. It offers cannabis and cannabis-derived products and technologies through licensed dispensaries to consumers in Arizona. It also operates and sells medical and adult-use cannabis dispensary franchises under the Unity Rd brand name. Item 9 Labs Corp. is headquartered in Phoenix, Arizona.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

60 shs

Market Capitalization

$70 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Item 9 Labs?

The following Wall Street analysts have issued research reports on Item 9 Labs in the last twelve months:
View the latest analyst ratings for INLB.

What is the current price target for Item 9 Labs?

0 Wall Street analysts have set twelve-month price targets for Item 9 Labs in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Item 9 Labs in the next year.
View the latest price targets for INLB.

What is the current consensus analyst rating for Item 9 Labs?

Item 9 Labs currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INLB.

What other companies compete with Item 9 Labs?

Other companies that are similar to Item 9 Labs include AllyMe Group, Alpha Tau Medical, Altair International, American Medical Technologies and Anzu Special Acquisition Corp I. Learn More about companies similar to Item 9 Labs.

How do I contact Item 9 Labs' investor relations team?

Item 9 Labs' physical mailing address is 2727 NORTH 3RD STREET SUITE 201, PHOENIX AZ, 85004. The company's listed phone number is 833-867-6337 and its investor relations email address is [email protected]. The official website for Item 9 Labs is www.item9labscorp.com. Learn More about contacing Item 9 Labs investor relations.